Biologic effectiveness increases with earlier biologic initiation after severe asthma onset Authors: Arjun Mohan, Reynold A Panettieri, Wendy C Moore, Njira L Lugogo, Wenjiong Zhou, Andrew W Lindsley, Donna D Carstens, Christopher S Ambrose Published: 2026 ABSTRACT AbstractBackgroundPatients with long-standing, uncontrolled, severe asthma can develop airway fibrosis and remodeling due to chronic inflammation, causing irreversible pulmonary damage.ObjectiveThis analysis evaluated the effect of the time from severe asthma onset to initiation of a biologic on treatment effectiveness in US patients with subspecialist-treated severe asthma.MethodsCHRONICLE (ClinicalTrials.gov identifier NCT03373045) was an observational study of US adults with subspecialist-treated severe asthma who were receiving biologics or maintenance systemic corticosteroids or had persistently uncontrolled asthma despite high-dose inhaled corticosteroids and additional controllers. Annualized asthma exacerbation rates in the 12 months before and 12 months after initiation of biologic treatment were compared. Factors with a univariate association (P < .1) with the rate of exacerbation during treatment (12 months after initiation) were included in a multivariable model to identify independent, statistically significant associations.ResultsThis analysis included 244 patients enrolled between February 2018 and February 2024 who initiated biologic treatment and had complete data. Exacerbation rates decreased by 59% from the pre–biologic initiation period to the post–biologic initiation period. Multivariable analyses demonstrated a significant association between the rate of exacerbation during treatment and time from severe asthma onset to initiation of treatment with a biologic (rate coefficient = 1.04 [95% CI = 1.02-1.07]; P < .001) after adjustment for the preinitiation exacerbation rate (rate coefficient = 1.48 [95% CI = 1.30-1.68]; P < .001) and Black versus White race (rate ratio: 2.40 [95% CI = 1.25-4.61]; P = .009).ConclusionWith adjustment for factors including prior exacerbations and race, a shorter time from severe asthma onset to initiation of a biologic was associated with a lower rate of exacerbation during treatment and increased effectiveness of treatment with a biologic.Key words: Allergists, biologic therapy, effectiveness, exacerbations, longitudinal, severe asthma, observational, pulmonologists, real-world Asthma is a heterogeneous disease with varying degrees of chronic airway inflammation, airway hyperresponsiveness, and reversible or fixed airflow obstruction.1 Approximately 10% of patients with asthma have severe disease, with symptoms either requiring treatment or remaining uncontrolled despite treatment with maximal standard-of-care therapies.2,3 Severe asthma contributes to a significant burden on individuals and health care services.4,5 Several biologic therapies targeting specific inflammatory pathways are approved in the United States for the treatment of severe asthma and are effective in reducing asthma exacerbations compared with placebo.6, 7, 8, 9, 10, 11 The efficacy of biologics in patients with severe asthma has been well established in randomized controlled trials and real-world studies.12, 13, 14, 15 Because of ongoing inflammation, patients with uncontrolled severe asthma, such as those with recurrent exacerbations, can develop airway fibrosis and remodeling over time, leading to irreversible impairments in pulmonary function.16,17 Additionally, a longitudinal follow-up study found an association between increased exacerbations and accelerated lung function decline in patients with asthma.18 This analysis evaluated how the time from severe asthma onset to initiation of a biologic was associated with rates of exacerbation during treatment and effectiveness of the biologic in a large, real-world cohort of US patients with subspecialist-treated severe asthma. Methods Study design and population The CHRONICLE study (ClinicalTrials.gov identifier NCT03373045; registration date November 20, 2017) was a real-world, prospective, observational study of US adults with subspecialist-treated severe asthma.19 Patients must have been receiving care from specialist physicians at the study site and had to have met 1 or more of the following criteria for inclusion: current use of a US Food and Drug Administration–approved biologic therapy for severe asthma; use of systemic corticosteroids or other systemic immunosuppressants for severe asthma for at least 50% of the prior 12 months; and persistently uncontrolled asthma (per the European Respiratory Society/American Thoracic Society guidelines)20 while being treated with high-dosage inhaled corticosteroids (ICSs) and additional controllers. The US Food and Drug Administration–approved biologics available for severe asthma and evaluated in this study were benralizumab (anti–IL-5 receptor [R]), dupilumab (anti–IL-4R), mepolizumab and reslizumab (anti–IL-5), omalizumab (anti-IgE), and tezepelumab (anti–thymic stromal lymphopoietin [TSLP]). Patients enrolled between February 2018 and February 2024 were included in the analysis if their 12-month pre–treatment initiation period was free of use of a biologic and the period following initiation of treatment with a biologic included continued use of that biologic for 12 months. The CHRONICLE study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices, Good Pharmacoepidemiology Practices, Health Insurance Portability and Accountability Act, and applicable legislation for observational studies. A signed informed consent form was obtained at enrollment for study participation and to acquire medical records, including pharmacy records, from other providers. Sex at birth, race, and ethnicity were obtained from patient medical records at screening. Outcomes This analysis evaluated whether the time from severe asthma onset to initiation of treatment with a biologic affected effectiveness of biologic treatment in reducing asthma exacerbations. Consistent with European Respiratory Society/American Thoracic Society guidelines,20 onset of severe asthma was defined as the best estimated date on which a patient first received treatment with a high-dosage ICS and additional controller medications, as reported by site staff on the basis of medical record review and medical history. The term high-dosage ICS was defined in the protocol as an ICS at a cumulative dose higher than 500 μg of fluticasone propionate equivalents daily or the highest labeled dose of a combination of an ICS and long-acting β-agonist. Asthma exacerbations were defined as asthma events requiring at least 3 days of oral corticosteroids or at least 1 corticosteroid injection (or a temporary increase in a stable, background dosage of oral corticosteroids), including those requiring an emergency department or urgent care visit or those requiring inpatient admission to a hospital owing to asthma and lasting at least 24 hours. Annualized exacerbation rates were calculated on the basis of number of exacerbations reported during the 12-month periods before or following initiation of treatment with a biologic. The 95% CIs for the annualized exacerbation rates were calculated on the basis of assumption of a Poisson distribution for the counts of exacerbations. Statistical analysis Descriptive statistics, including percentages, means, SDs, medians, and quartiles, were reported for patient characteristics. Patient characteristics were evaluated overall and by the time from severe asthma onset to the initiation of biologic therapy; patients were grouped into 3 categories representing the lower, middle, and upper tertiles of the distribution (shorter, moderate, and longer time intervals, respectively). P values were derived from a mean difference among the tertile groups based on an F-test for continuous variables and a chi-square test for categoric variables. Calculations excluded the data from the categories Missing, Unknown, and Prefer not to answer, or sparse data such as the categories non-White or non-Black for race and the category Uninsured for primary insurance status. A locally estimated scatterplot smoothing (LOESS) analysis was used to describe the relationship between the percentage of reduction in the exacerbation rate and the time from severe asthma onset to initiation of biologic therapy. A LOESS plot was generated for biologics overall and for the subgroups of anti–IL-4R/anti-TSLP and anti–IL-5/anti–IL-5R biologics to determine whether the results were similar across biologic mechanisms (individual biologics could not be examined owing to the limited sample sizes). The limited study sample size for the anti-IgE biologic omalizumab prevented robust estimates for a LOESS plot. Reduction in exacerbation rate was calculated by comparing the rates for the 12 months before and the 12 months after initiation of treatment with a biologic. A univariate analysis was conducted to evaluate the effect of the following individual factors on effectiveness of using a biologic in reducing the exacerbation rate: age at screening, age at asthma diagnosis, age at initiation of a biologic, time from the date of severe asthma onset to the date of initial use of a biologic, asthma exacerbation count during the 12 months before initiation of a biologic, sex, race, ethnicity, residential area, primary insurance status, class of biologic initiated, receipt of maintenance systemic corticosteroids, body mass index before initiation of a biologic, blood eosinophil count, and total IgE levels. Subsequently, factors with a univariate association (P < .1) with the exacerbation rate during the 12-month during-treatment period (while a patient was receiving a biologic) were further evaluated in a stepwise manner in a multivariable model to identify the final factors with a statistically significant (P < .05) association with the exacerbation rate during the 12 months after initiation. A threshold of P less than .1 was used in the univariate analysis to reduce the risk of excluding important individual predictors whose association with the outcome might become apparent only when adjusted for other variables in the multivariable model.21 In both univariate and multivariate analyses, rate coefficients were used to quantify the magnitude of the change in exacerbation rate per unit change in each continuous covariate. Rate ratios were used to assess the impact of the categoric covariates on the change in exacerbation rate. Results Patient demographics and clinical characteristics Of the 5089 eligible patients screened across 141 sites, 4064 were enrolled in the CHRONICLE study. This analysis included all patients (N = 244) enrolled between February 2018 and February 2024 who initiated biologic treatment and had complete data for the 12 months before and 12 months after initiation of treatment with a biologic (Table I). Overall, the mean (SD) age was 53.1 (± 15.0) years at enrollment and 48.0 (± 16.9) years at severe asthma onset. Most patients had an age at onset of severe asthma of 40 to 65 years (Fig 1). The majority of patients were female (65.2%), White (76.8%), and not Hispanic or Latino (95.9%). Patients most commonly lived in suburban areas (42.7%) and had private health insurance (61.2%) (Table I). Table IDemographic and clinical characteristics for patients with severe asthma who had data for at least 12 months before and at least 12 months after initiation of a biologicCharacteristicPatients with shorter time from severe asthma onset to use of a biologic (n = 81)Patients with moderate time from severe asthma onset to use of a biologic (n = 81)Patients with longer time from severe asthma onset to use of a biologic (n = 82)P value comparing differences in demographic characteristic∗All patients (N = 244)Age at screening (y)Mean (SD)50.7 (15.3)53.0 (14.9)55.7 (14.7).10353.1 (15.0) Median (IQR)51.0 (43.0-61.0)53.0 (44.0-64.0)57.5 (48.0-64.0)54.5 (45.0-64.0) Minimum, maximum18, 8718, 8018, 8218, 87Age at severe asthma onset (y), Mean (SD)50.5 (15.2)50.7 (15.3)42.7 (18.8).00248.0 (16.9) Median (IQR)50.8 (42.6-61.6)51.6 (43.6-61.4)47.0 (27.1-57.0)49.9 (38.2-59.4) Minimum, maximum19, 8712, 792, 762, 87Age at initiation of a biologic (y), Mean (SD)51.5 (15.2)54.5 (15.1)57.3 (14.7).04954.5 (15.1) Median (IQR)51.7 (43.6-62.1)55.2 (46.8-64.9)59.0 (48.8-66.7)56.1 (46.1-64.8) Minimum, maximum19, 8818, 8118, 8318, 88Time from date of severe asthma onset to date of initiation of a biologic (y), mean (SD)1.0 (0.56)3.8 (1.17)14.7 (8.94)< .0016.5 (7.88)Asthma exacerbation count in the 12 months before initiation of a biologic, mean (SD)1.1 (1.12)1.3 (1.64)1.1 (1.44).4161.2 (1.42)Sex, n (%) Female59 (72.8)47 (58.0)53 (64.6).140159 (65.2) Male22 (27.2)34 (42.0)29 (35.4)85 (34.8)Race, n (%)† N767478228 Black19 (25.0)21 (28.4)13 (16.7).21153 (23.2) White57 (75.0)53 (71.6)65 (83.3)175 (76.8) Other‡33410 Not reported2406Ethnicity, n (%) Hispanic or Latino4 (4.9)3 (3.7)3 (3.7).89710 (4.1) Not Hispanic or Latino77 (95.1)78 (96.3)79 (96.3)234 (95.9)Residential area, n (%)† N757978232 Urban24 (32.0)25 (31.6)21 (26.9).28570 (30.2) Rural23 (30.7)24 (30.4)16 (20.5)63 (27.2) Suburban28 (37.3)30 (38.0)41 (52.6)99 (42.7) Missing62412Primary insurance status, n (%)† N818081242 Medicare or other federal (non-Medicaid)18 (22.2)20 (25.0)19 (23.5).32957 (23.6) Medicaid15 (18.5)15 (18.8)7 (8.6)37 (15.3) Private48 (59.3)45 (56.3)55 (67.9)148 (61.2) Uninsured0011 Missing0101Biologic class initiated, n (%) Anti-IgE12 (14.8)15 (18.5)11 (13.4).83838 (15.6) Anti–IL-4R/anti-TSLP26 (32.1)28 (34.6)31 (37.8)85 (34.8) Anti–IL-5/anti–IL-5R43 (53.1)38 (46.9)40 (48.8)121 (49.6)Patients receiving maintenance systemic corticosteroids, n (%)11 (13.6)17 (21.0)16 (19.5).43044 (18.0)Body mass index before initiation of a biologic, (kg/m2), mean (SD)33.9 (8.1)33.2 (6.9)32.5 (8.3).49633.2 (7.8)Blood eosinophil count (K/μL) N706260192 Mean (SD)484.5 (514.1)576.5 (789.3)541.7 (630.1).712532.1 (647.0) Median (IQR)371.5 (198.0-607.7)365.1 (182.0-714.0)399.2 (169.3-605.8)375.1 (183.0-645.3) < 300, n (%)28 (40.0)26 (41.9)25 (41.7).97079 (41.1) ≥ 300, n (%)42 (60.0)36 (58.1)35 (58.3)113 (58.9)Blood eosinophil count, (K/μL) log2 N686157186 Mean (SD)8.5 (1.18)8.3 (1.77)8.5 (1.50).7598.4 (1.49)Total IgE (IU/mL) N494341133 Mean (SD)286.5 (410.8)372.9 (651.5)317.1 (627.2).763323.9 (563.0) Median (IQR)154.0 (40.0-338.0)147.0 (54.8-399.0)76.0 (35.0-249.0)120.0 (40.0-327.0)Prebronchodilator FEV1, % predicted N747777228 Mean (SD)71.4 (21.1)71.8 (22.7)65.3 (21.2).11869.4 (21.8)IQR, Interquartile range.∗P values were derived from a mean difference among the tertile groups based on the F-test for continuous variables and chi-square test for categoric variables.†Calculations excluded the data from the categories Missing, Unknown, and Prefer not to answer or from sparse data such as the categories non-White or non-Black for race and the category Uninsured for primary insurance status.‡Other includes Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and other. Demographic and clinical characteristics for patients with severe asthma who had data for at least 12 months before and at least 12 months after initiation of a biologic IQR, Interquartile range. P values were derived from a mean difference among the tertile groups based on the F-test for continuous variables and chi-square test for categoric variables. Calculations excluded the data from the categories Missing, Unknown, and Prefer not to answer or from sparse data such as the categories non-White or non-Black for race and the category Uninsured for primary insurance status. Other includes Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and other. Distribution of patient age at the onset of severe asthma. Patients included in the analysis had severe asthma for at least 12 months before enrollment, with investigator confirmation that severe asthma symptoms were not due to an alternative diagnosis. The numbers of patients within each age category are displayed above their respective bars. Most baseline demographics and clinical characteristics were similar across patients with a shorter (mean 1.0 ± 0.56 years), moderate (mean 3.8 ± 1.17 years), or longer (mean 14.7 ± 8.94 years]) time from asthma onset to use of a biologic (Table I). Those patients with a shorter or moderate time from severe asthma onset to use of a biologic were significantly (P = .002) older at the time of severe asthma onset (mean ages 50.5 and 50.7 years, respectively) than those with a longer time from severe asthma onset to use of a biologic (42.7 years) (Table I). Age at initiation of a biologic was also significantly (P = .049) associated with time from severe asthma onset to use of a biologic (Table I). The pre–biologic initiation period exacerbation rates were similar across tertiles, ranging from 1.1 to 1.3 exacerbations per year. In total, 38 patients (15.6%) started biologic treatment with an anti-IgE (omalizumab), 121 patients (49.6%) received treatment with an anti–IL-5/anti–IL-5R (75 patients [30.7%] received benralizumab, 45 patients [18.4%] received mepolizumab, and 1 patient [0.4%] received reslizumab), and 85 patients (34.8%) received treatment with either an anti–IL-4R or an anti-TSLP biologic (71 patients [29.1%] received dupilumab and 14 patients [5.7%] received tezepelumab). Overall, the rate of reported exacerbations decreased by 59% from the pre–biologic initiation period to the post–biologic initiation period (annualized rates of 1.16 [95% CI = 1.03-1.31] and 0.47 [95% CI = 0.39-0.57], respectively). The LOESS analysis showed a diminished reduction in exacerbation rate (decreased effectiveness of using a biologic) with increasing time from the date of severe asthma onset to initiation of a biologic (Fig 2). This decrease in effectiveness of using a biologic with increasing years from severe asthma onset was seen with both anti–IL-4R/anti-TSLP and anti–IL-5/anti–IL-5R biologics (see Fig E1 in the Online Repository at www.jaci-global.org). Decreased effectiveness of use of a biologic with increasing years from severe asthma onset to initiation of treatment with a biologic. The solid line represents the effectiveness of using a biologic based on LOESS regression, and the shaded area represents the corresponding 95% CI. The 95% CIs are truncated at 0% and 100%. Univariate and multivariable analyses of factors associated with the during-treatment exacerbation rate All factors included in the univariate analysis are listed in Table II. The factors that were associated (P < .1) with the during-treatment exacerbation rate in the univariate analysis were exacerbation count in the 12 months before initiation of a biologic (rate coefficient = 1.52 [95% CI = 1.34-1.73]; P < .001 [representing a 52% increase in exacerbation rate per additional exacerbation before initiation of a biologic]), age at screening (rate coefficient = 0.98 [95% CI = 0.96-1.00]; P = .098 [a 2% decrease in exacerbation rate per 1-year increase in age]), age at first asthma diagnosis (rate coefficient = 0.98 [95% CI = 0.97-1.00]; P = .026 [a 2% decrease in exacerbation rate per 1-year increase in age]), age at initiation of a biologic (rate coefficient = 0.98 [95% CI = 0.97-1.00]; P = .098 [a 2% decrease in exacerbation rate per 1-year increase in age]), time from severe asthma onset to initiation of a biologic (rate coefficient = 1.03 [95% CI = 1.01-1.06; P = .003 [a 3% increase in exacerbation rate per 1-year increase in time]), and race (rate ratio for Black and other races vs White = 2.52 [95% CI = 1.32-4.81]; P = .006) (Table II). Both Hispanic or Latino ethnicity and total IgE level were associated with the rate of exacerbation during treatment (P < .1) but were not included in the multivariable analysis because of low representation and high levels of missing data, respectively. Table IIUnivariate analysis of factors with the during-treatment exacerbation rate in the 12 months after initiation of a biologicFactorRate coefficient/rate ratio (95% CI)P valueAge at screening (y) (n = 244)0.98 (0.96-1.00).098Age at first asthma diagnosis (y) (n = 234)0.98 (0.97-1.00).026Age at initiation of a biologic (y) (n = 244)0.98 (0.97-1.00).098Time from date of severe asthma onset to date of initiation of a biologic (y) (n = 244)1.03 (1.01-1.06).003Asthma exacerbation count during the 12 months before initiation of a biologic (n = 244)1.52 (1.34-1.73)< .001Sex, female (n = 159) vs male (n = 85)1.34 (0.62-2.93).455Black (n = 53) and other∗ race (n = 10) vs White (n = 175)2.52 (1.32-4.81).006Ethnicity, Hispanic or Latino (n = 10) vs not Hispanic or Latino (n = 234)0.20 (0.03-1.35).099Residential area Rural (n = 63) vs urban (n = 70)0.62 (0.32-1.23).371 Suburban (n = 99) vs urban (n = 70)0.85 (0.41-1.75)Primary insurance status Medicare or other federal (non-Medicaid) (n = 57) vs private (n = 148)0.90 (0.43-1.89).339 Medicaid (n = 37) vs private (n = 148)1.64 (0.78-3.44)Biologic class initiated Anti–IL-4R/anti-TSLP (n = 85) vs anti-IgE (n = 38)0.55 (0.21-1.44).381 Anti–IL-5/anti–IL-5R (n = 121) vs anti-IgE (n = 38)0.55 (0.23-1.30)Receipt of maintenance systemic corticosteroids, yes (n = 44) vs no (n = 200)1.06 (0.51-2.24).870Body mass index before initiation of a biologic (kg/m2) (n = 233)1.00 (0.96-1.04).958Blood eosinophil count (K/μL) log2, (n = 186)1.08 (0.85-1.36).530IgE (IU/mL) log2, (n = 133)0.88 (0.78-0.99).029∗Other includes Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, and other. Univariate analysis of factors with the during-treatment exacerbation rate in the 12 months after initiation of a biologic Other includes Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, and other. Subsequently, a multivariable analysis identified independent, statistically significant associations between factors and the rate of exacerbation during treatment in patients with severe asthma during the 12 months after initiation of a biologic (Table III). The rate of exacerbation during treatment was significantly associated with the exacerbation rate in the 12 months before initiation of a biologic (rate coefficient = 1.48 [95% CI = 1.30-1.68]; P < .001); for every additional exacerbation before initiation of a biologic, there was a 48% increase in the rate of exacerbation during treatment. The during-treatment exacerbation rate was also significantly associated with the time from severe asthma onset to initiation of a biologic in the 12 months before initiation of a biologic (rate coefficient = 1.04 [95% CI = 1.02-1.07]; P = < .001); for every patient year increase in time from severe asthma onset to initiation of a biologic, there was a 4% decrease in effectiveness of using a biologic in the during-treatment period. Compared with White race (n = 168), Black race (n = 52) was also significantly associated with the during-treatment exacerbation rate (rate ratio = 2.40 [95% CI = 1.25-4.61]; P = .009). Table IIIMultivariable analysis of factors significantly (P < .05) associated with the rate of exacerbation during treatment in the 12 months after initiation of a biologicFactorRate coefficient/rate ratio (95% CI)P valueAsthma exacerbation count during the 12 months before initiation of a biologic (n = 220)1.48 (1.30-1.68)< .001Time from date of severe asthma onset to date of use of a biologic (each additional year) (n = 220)1.04 (1.02-1.70)< .001Black (n = 52) vs White (n = 168) race2.40 (1.25-4.61).009The rate of asthma exacerbation count was per additional exacerbation before initiation of treatment with a biologic, and the rate of time from severe asthma onset to use of a biologic was per 1–patient–year increase. Multivariable analysis of factors significantly (P < .05) associated with the rate of exacerbation during treatment in the 12 months after initiation of a biologic The rate of asthma exacerbation count was per additional exacerbation before initiation of treatment with a biologic, and the rate of time from severe asthma onset to use of a biologic was per 1–patient–year increase. Discussion These findings suggest that the time from severe asthma onset to initiation of treatment with a biologic may affect the effectiveness of using a biologic, a finding that was consistent across different biologic mechanisms. Although age at asthma onset was identified in the univariate analyses as a factor associated with the during-treatment exacerbation rate, it was not statistically significant in the multivariable analyses. Patients with long-standing severe asthma may experience potentially irreversible airway remodeling and other longer-term detrimental effects that may reduce their response to biologic treatment.17 Previous studies have shown that early intervention with biologic treatments may help to preserve lung function and improve patient outcomes.18,22, 23, 24 A pooled analysis of patients with severe, uncontrolled asthma and abnormal lung function from the phase 2 PATHWAY and phase 3 NAVIGATOR studies found that among those receiving tezepelumab, those with a shorter asthma duration (< 20 years) at baseline were more likely to achieve normal lung function than were those with a longer asthma duration (≥ 20 years).25 Similarly, earlier intervention with mepolizumab has been associated with better preservation of lung function.22 In addition, a longitudinal cohort study using data from the International Severe Asthma Registry reported that patients with severe asthma who had less-severe disease (including fewer prior-year exacerbations) and a shorter asthma duration before initiation of a biologic were more likely to achieve clinical remission within 12 months after starting treatment.26 The current analysis found that increased time from severe asthma onset to starting treatment with a biologic was associated with a lower reduction in asthma exacerbation rate. Several factors, including race, ethnicity, socioeconomic factors, and health insurance status, could contribute to delays in receiving biologic treatment. Among these, however, only race showed a statistically significant association with during-treatment exacerbation rates in multivariate analyses. A previous study showed that Black patients experience a disproportionate burden of asthma compared with White patients, with Black patients more frequently experiencing exacerbations requiring emergency department visits or hospitalizations.27 Given our findings of increased effectiveness of using a biologic and reduced exacerbation rates with shorter time from severe asthma onset to initiation of a biologic, barriers preventing timely access to biologic therapies for eligible patients with severe uncontrolled asthma should be minimized wherever possible. A previous analysis of the CHRONICLE study showed that the incidence of asthma exacerbations decreased during the coronavirus disease 2019 (COVID-19) pandemic. In 2020, the exacerbation rates from April through August were 20% to 52% lower than for the same period in 2019, likely thanks to public health measures such as stay-at-home orders, social distancing, and increased mask use.28 However, in the current analysis, pre–biologic initiation exacerbation rates were consistent across cohorts, with shorter, moderate, and longer times from severe asthma onset to initiation of use of a biologic. This suggests that the COVID-19 pandemic reduction in exacerbation rates did not meaningfully influence the study’s findings. As previously described,19,29 the limitations of the CHRONICLE study are related to study site differences in the standard of care and the lack of random site selection. In the current study cohort, 21.7% of the enrolled patients were Black, 71.7% were White, and 4.1% were Hispanic or Latino, a distribution that more closely reflects the demographics of the US population than most clinical trials do.30 However, the Hispanic or Latino population was clearly underrepresented, given that approximately 20% of the US population reports Hispanic or Latino ethnicity. Additionally, the data used for this analysis were obtained from subspecialist-treated US adults with severe asthma, as a result of which the findings may not be generalizable on a wider scale. All patients enrolled in CHRONICLE were receiving ongoing care at the enrolling site. The reported date of onset of severe asthma was determined by site investigators on the basis of their assessment of each patient’s medical and treatment history. Sites were not required to use pharmacy database records to confirm this information. Given the study protocol definition of a high-dosage ICS, patients receiving maintenance and reliever therapy were unlikely to have been considered eligible to participate in the study unless their daily maintenance dose met the criteria for a high-dosage ICS. Although the reported onset of severe asthma may have been misestimated in some cases, the data reported are expected to reflect the best available assessment from routine care by US subspecialists treating severe asthma. The investigator-identified onset of severe asthma used in this analysis may differ from the onset of uncontrolled severe asthma that would warrant potential biologic treatment. Additionally, the study captured age at asthma diagnosis as a patient characteristic and did not capture information regarding the age of onset of asthma symptoms. Accordingly, how long patients may have been experiencing intermittent symptoms and exacerbations, as well as a potential decline in lung function before receiving a formal diagnosis and treatment, is unknown. With adjustment for other factors, a shorter time from severe asthma onset to initiation of treatment with a biologic was associated with a lower during-treatment exacerbation rate and increased effectiveness of using a biologic. This finding suggests that there may be benefits from accelerating initiation of treatment with a biologic among patients with severe asthma to avoid long-term and potentially irreversible airway remodeling from insufficiently treated inflammation and improve patient outcomes. Clinical implications Shorter time from severe asthma onset to initiation of a biologic was associated with reduced rates of exacerbation during treatment and increased effectiveness of using a biologic, highlighting the importance of timely access to biologic treatments. Disclosure statement The study sponsors, AstraZeneca and Amgen, contributed to the study design and data interpretation and provided funding for medical writing assistance. AstraZeneca conducted the study and coordinated the data management and statistical analysis in collaboration with investigators at academic centers. Data sharing statement: The data supporting the findings of this study are available from the corresponding author on reasonable request. Individuals who were or were not involved in the CHRONICLE study may submit publication proposals to the study’s publication steering committee by contacting the corresponding author. Disclosure of potential conflict of interest: A. Mohan has participated in advisory boards for Regeneron Pharmaceuticals and Verona Pharma. R. A. Panettieri Jr has participated in advisory boards for and received grant support from AstraZeneca, Genentech, Novartis, Regeneron Pharmaceuticals, and Sanofi. W. C. Moore has participated in advisory boards for AstraZeneca, GSK, Regeneron Pharmaceuticals, and Sanofi; in addition, she has received grant support from Areteia Therapeutics; AstraZeneca; Boehringer Ingelheim; Genentech; GSK; the National Heart, Lung, and Blood Institute (National Institutes of Health); Regeneron Pharmaceuticals, Sanofi, and Teva Pharmaceuticals. N. L. Lugogo has participated in advisory boards for Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, Sanofi, and Teva Pharmaceuticals; in addition, she has received the following: fees for non–speaker bureau presentations from AstraZeneca and GSK; speaker fees (her own content) from NIOX group; travel support from AstraZeneca; and grant support from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals, Sanofi, and Teva Pharmaceuticals. W. Zhou is a consultant for ClinChoice, which was contracted by AstraZeneca for statistical analysis. A. W. Lindsley is an employee and shareholder of Amgen. D. D. Carstens and C. S. Ambrose are employees and shareholders of AstraZeneca. Acknowledgments Medical writing support was provided by Richa B. Tripathi, PhD, of Oxford PharmaGenesis (London, UK), and Elizabeth Gandhi, PhD, of Oxford PharmaGenesis (Cambridge, UK), which was in accordance with Good Publication Practice (GPP 2022) guidelines and funded by AstraZeneca (Wilmington, Del). Supplementary data Supplementary Fig E1 Supplementary Figure Legend References Associated Data Supplementary Materials Supplementary Fig E1 Supplementary Figure Legend